NewLink Genetics Stock Price, Forecast & Analysis (NASDAQ:NLNK)

NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK."

NewLink Genetics Corp (NASDAQ:NLNK) announced its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.27). The biotechnology company had revenue of $0.25 million for the quarter. NewLink Genetics had a negative return on equity of 40.06% and a negative net margin of 6,423.69%. View NewLink Genetics' Earnings History.

NewLink Genetics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for NewLink Genetics.

2 analysts have issued 12-month price targets for NewLink Genetics' stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate NewLink Genetics' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 156.4% from the stock's current price. View Analyst Price Targets for NewLink Genetics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NewLink Genetics in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NewLink Genetics.

News coverage about NLNK stock has been trending very negative on Monday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NewLink Genetics earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for NewLink Genetics.

NewLink Genetics saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,890,000 shares, an increase of 5.6% from the September 30th total of 1,790,000 shares. Based on an average daily volume of 302,600 shares, the short-interest ratio is presently 6.2 days. Approximately 6.5% of the shares of the stock are short sold. View NewLink Genetics' Current Options Chain.

Some companies that are related to NewLink Genetics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other NewLink Genetics investors own include Synergy Pharmaceuticals (SGYP), Arbutus Biopharma (ABUS), Inovio Pharmaceuticals (INO), SunPower (SPWR), Sarepta Therapeutics (SRPT), Celldex Therapeutics (CLDX), Alibaba Group (BABA), FireEye (FEYE), Novavax (NVAX) and Opko Health (OPK).

NewLink Genetics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Tower Research Capital LLC TRC (0.09%) and Wedbush Securities Inc. (0.07%). Company insiders that own NewLink Genetics stock include Carl W Langren and Ernest Talarico III. View Institutional Ownership Trends for NewLink Genetics.

NLNK stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc. and Tower Research Capital LLC TRC . View Insider Buying and Selling for NewLink Genetics.

Shares of NLNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NLNK stock can currently be purchased for approximately $1.56.

NewLink Genetics has a market capitalization of $58.21 million and generates $12.47 million in revenue each year. The biotechnology company earns $-53,600,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. NewLink Genetics employs 55 workers across the globe.View Additional Information About NewLink Genetics.

The official website for NewLink Genetics is http://www.newlinkgenetics.com/.

NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE, AMES IA, 50010. The biotechnology company can be reached via phone at 515-296-5555 or via email at [email protected]